Girard Partners Ltd. Bristol Myers Squibb CO Transaction History

Girard Partners Ltd.

$1.06 Billion
Q2 2024

A detailed history of Girard Partners Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Girard Partners Ltd. holds 26,013 shares of BMY stock, worth $1.46 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

26,013

Previous 28,605 9.06%

Holding current value

$1.46 Million

Previous $1.55 Million 30.37%

% of portfolio

0.1%

Previous 0.15%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$40.25 - $52.99 $104,328 - $137,350	-2,592 Reduced 9.06%	26,013 $1.08 Million
Q1 2024 May 13, 2024	SELL	$47.98 - $54.4 $94,184 - $106,787	-1,963 Reduced 6.42%	28,605 $1.55 Million
Q4 2023 Feb 09, 2024	SELL	$48.48 - $57.85 $138,604 - $165,393	-2,859 Reduced 8.55%	30,568 $1.57 Million
Q3 2023 Nov 02, 2023	BUY	$57.89 - $64.73 $85,561 - $95,670	1,478 Added 4.63%	33,427 $1.94 Million
Q2 2023 Aug 15, 2023	BUY	$63.71 - $70.74 $207,248 - $230,117	3,253 Added 11.34%	31,949 $2.04 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $109,998 - $124,763	-1,674 Reduced 5.51%	28,696 $1.99 Million
Q4 2022 Jan 26, 2023	BUY	$68.48 - $81.09 $133,125 - $157,638	1,944 Added 6.84%	30,370 $0
Q3 2022 Oct 20, 2022	SELL	$0.13 - $76.84 $23 - $13,984	-182 Reduced 0.64%	28,426 $2.02 Million
Q2 2022 Jul 26, 2022	BUY	$72.62 - $79.98 $1.8 Million - $1.98 Million	24,760 Added 643.45%	28,608 $2.2 Million
Q1 2022 Apr 27, 2022	SELL	$61.48 - $73.72 $10,513 - $12,606	-171 Reduced 4.25%	3,848 $281,000
Q4 2021 Feb 02, 2022	SELL	$53.63 - $62.52 $9,867 - $11,503	-184 Reduced 4.38%	4,019 $250,000
Q3 2021 Nov 01, 2021	BUY	$59.17 - $69.31 $234,017 - $274,121	3,955 Added 1594.76%	4,203 $248,000
Q3 2021 Nov 01, 2021	SELL	$59.17 - $69.31 $254,194 - $297,755	-4,296 Reduced 94.54%	248 $248,000
Q2 2021 Aug 10, 2021	SELL	$61.91 - $67.42 $41,293 - $44,969	-667 Reduced 12.8%	4,544 $303,000
Q1 2021 May 06, 2021	SELL	$59.34 - $66.74 $102,124 - $114,859	-1,721 Reduced 24.83%	5,211 $329,000
Q4 2020 Feb 02, 2021	SELL	$57.74 - $65.43 $68,768 - $77,927	-1,191 Reduced 14.66%	6,932 $429,000
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $157,587 - $174,628	-2,744 Reduced 25.25%	8,123 $489,000
Q2 2020 Aug 10, 2020	SELL	$54.82 - $64.09 $233,039 - $272,446	-4,251 Reduced 28.12%	10,867 $639,000
Q1 2020 May 01, 2020	SELL	$46.4 - $67.43 $322,201 - $468,233	-6,944 Reduced 31.47%	15,118 $842,000
Q4 2019 Feb 03, 2020	BUY	$49.21 - $64.19 $403,768 - $526,678	8,205 Added 59.21%	22,062 $1.42 Million
Q3 2019 Nov 01, 2019	SELL	$42.77 - $50.71 $409,822 - $485,903	-9,582 Reduced 40.88%	13,857 $702,000
Q2 2019 Aug 12, 2019	BUY	$44.62 - $49.34 $182,495 - $201,800	4,090 Added 21.14%	23,439 $1.06 Million
Q1 2019 May 08, 2019	SELL	$45.12 - $53.8 $9,339 - $11,136	-207 Reduced 1.06%	19,349 $923,000
Q4 2018 Feb 11, 2019	SELL	$48.76 - $63.23 $110,538 - $143,342	-2,267 Reduced 10.39%	19,556 $1.02 Million
Q3 2018 Nov 09, 2018	SELL	$55.19 - $62.25 $308,788 - $348,288	-5,595 Reduced 20.41%	21,823 $1.35 Million
Q2 2018 Aug 07, 2018	SELL	$50.53 - $62.98 $57,048 - $71,104	-1,129 Reduced 3.95%	27,418 $1.52 Million
Q1 2018 Apr 18, 2018	SELL	$59.92 - $68.98 $44,820 - $51,597	-748 Reduced 2.55%	28,547 $1.81 Million
Q4 2017 Feb 07, 2018	SELL	$59.94 - $65.35 $48,491 - $52,868	-809 Reduced 2.69%	29,295 $1.8 Million
Q3 2017 Nov 08, 2017	SELL	$55.23 - $63.74 $135,810 - $156,736	-2,459 Reduced 7.55%	30,104 $1.92 Million
Q2 2017 Aug 08, 2017	BUY	N/A	32,563	32,563 $1.81 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Girard Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Girard Partners Ltd. with notifications on news.

Account

Girard Partners Ltd. Bristol Myers Squibb CO Transaction History